BACKGROUND: The organic anion transporting polypeptides (OATP)/SLCO family represents an important class of hepatic drug uptake transporters that mediate the sodium independent transport of a diverse range of amphipathic organic compounds, including the protease inhibitors. The SLCO1B1 521T>C (rs4149056) single nucleotide polymorphism (SNP) has been consistently associated with reduced transport activity in vivo, and we previously showed an association of this polymorphism with lopinavir plasma concentrations. The aim of this study was to develop a population pharmacokinetic (PK) model to quantify the impact of 521T>C. METHODS: A population PK analysis was performed with 594 plasma samples from 375 patients receiving lopinavir/ritonavir. Non-linear mixed effects modelling was applied to explore the effects of SLCO1B1 521T>C and patient demographics. Simulations of the lopinavir concentration profile were performed with different dosing regimens considering the different alleles. RESULTS: A one-compartment model with first-order absorption best described the data. Population clearance was 5.67 l/h with inter-patient variability of 37%. Body weight was the only demographic factor influencing clearance, which increased 0.5 l/h for every 10 kg increase. Homozygosity for the C allele was associated with a 37% lower clearance, and 14% for heterozygosity, which were statistically significant. CONCLUSIONS: These data show an association between SLCO1B1 521T>C and lopinavir clearance. The association is likely to be mediated through reduced uptake by hepatocytes leading to higher plasma concentrations of lopinavir. Further studies are now required to confirm the association and to assess the influence of other polymorphisms in the SLCO family on lopinavir PK.
BACKGROUND: The organic anion transporting polypeptides (OATP)/SLCO family represents an important class of hepatic drug uptake transporters that mediate the sodium independent transport of a diverse range of amphipathic organic compounds, including the protease inhibitors. The SLCO1B1 521T>C (rs4149056) single nucleotide polymorphism (SNP) has been consistently associated with reduced transport activity in vivo, and we previously showed an association of this polymorphism with lopinavir plasma concentrations. The aim of this study was to develop a population pharmacokinetic (PK) model to quantify the impact of 521T>C. METHODS: A population PK analysis was performed with 594 plasma samples from 375 patients receiving lopinavir/ritonavir. Non-linear mixed effects modelling was applied to explore the effects of SLCO1B1 521T>C and patient demographics. Simulations of the lopinavir concentration profile were performed with different dosing regimens considering the different alleles. RESULTS: A one-compartment model with first-order absorption best described the data. Population clearance was 5.67 l/h with inter-patient variability of 37%. Body weight was the only demographic factor influencing clearance, which increased 0.5 l/h for every 10 kg increase. Homozygosity for the C allele was associated with a 37% lower clearance, and 14% for heterozygosity, which were statistically significant. CONCLUSIONS: These data show an association between SLCO1B1 521T>C and lopinavir clearance. The association is likely to be mediated through reduced uptake by hepatocytes leading to higher plasma concentrations of lopinavir. Further studies are now required to confirm the association and to assess the influence of other polymorphisms in the SLCO family on lopinavir PK.
Authors: Laura Dickinson; Marta Boffito; David Back; Laura Else; Nils von Hentig; Geraint Davies; Saye Khoo; Anton Pozniak; Graeme Moyle; Leon Aarons Journal: Antimicrob Agents Chemother Date: 2011-03-21 Impact factor: 5.191
Authors: Laura Dickinson; Lesley Robinson; John Tjia; Saye Khoo; David Back Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2005-10-13 Impact factor: 3.205
Authors: Mikko Niemi; Janne T Backman; Lauri I Kajosaari; Julian B Leathart; Mikko Neuvonen; Ann K Daly; Michel Eichelbaum; Kari T Kivistö; Pertti J Neuvonen Journal: Clin Pharmacol Ther Date: 2005-06 Impact factor: 6.875
Authors: A I Veldkamp; G J Weverling; J M Lange; J S Montaner; P Reiss; D A Cooper; S Vella; D Hall; J H Beijnen; R M Hoetelmans Journal: AIDS Date: 2001-06-15 Impact factor: 4.177
Authors: G A Kullak-Ublick; B Hagenbuch; B Stieger; C D Schteingart; A F Hofmann; A W Wolkoff; P J Meier Journal: Gastroenterology Date: 1995-10 Impact factor: 22.682
Authors: Holger Bronger; Jörg König; Kathrin Kopplow; Hans-Herbert Steiner; Rezvan Ahmadi; Christel Herold-Mende; Dietrich Keppler; Anne T Nies Journal: Cancer Res Date: 2005-12-15 Impact factor: 12.701
Authors: José Moltó; Manuel José Barbanoj; Cristina Miranda; Asunción Blanco; José Ramón Santos; Eugenia Negredo; Joan Costa; Pere Domingo; Bonaventura Clotet; Marta Valle Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447
Authors: Jorge A Pinto; Edmund V Capparelli; Meredith Warshaw; Bonnie Zimmer; Tim R Cressey; Stephen A Spector; Min Qin; Betsy Smith; George K Siberry; Mark Mirochnick Journal: Pediatr Infect Dis J Date: 2018-02 Impact factor: 2.129
Authors: Bhagwat Prasad; Raymond Evers; Anshul Gupta; Cornelis E C A Hop; Laurent Salphati; Suneet Shukla; Suresh V Ambudkar; Jashvant D Unadkat Journal: Drug Metab Dispos Date: 2013-10-11 Impact factor: 3.922
Authors: José Moltó; George Xinarianos; Cristina Miranda; Sudeep Pushpakom; Samandhy Cedeño; Bonaventura Clotet; Andrew Owen; Marta Valle Journal: Clin Pharmacokinet Date: 2013-07 Impact factor: 6.447
Authors: B Prasad; A Gaedigk; M Vrana; R Gaedigk; J S Leeder; L Salphati; X Chu; G Xiao; Ceca Hop; R Evers; L Gan; J D Unadkat Journal: Clin Pharmacol Ther Date: 2016-08-13 Impact factor: 6.875